A recent study showed increased efficacy of TKI, cabozantinib, or anti-PD-1 checkpoint-inhibition, when combined with an anti-IL-1β mAb in a heterotopic mouse model of RCC [255]. This evidence concerns the gene IL1B and renal cell carcinoma.